- Cardiac Electrophysiology Key Opinion Leaders joining the
webcast include A. John Camm, MD,
and Sean Pokorney, MD
- Conference call and webcast on Monday, November 13, 2023 at 8:00 a.m. ET
MONTREAL and CHARLOTTE,
N.C., Nov. 7, 2023 /PRNewswire/ -- Milestone
Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the
Company will host a virtual investor and analyst webcast on
Monday, November 13, 2023 at
8:00 a.m. ET. The webcast will focus
on results from the ReVeRA Phase 2 study of investigational new
drug etripamil in patients with atrial fibrillation with rapid
ventricular rate (AFib-RVR), which is being presented as a Featured
Science presentation at the American Heart Association (AHA)
Scientific Sessions 2023.
Joining Milestone's management team will be:
- A. John Camm, M.D., Author on
the ReVeRA AHA Featured Science presentation and British Heart
Foundation Emeritus Professor of Clinical Cardiology, The
Cardiology Clinical Academic Group, Molecular and Clinical Sciences
Research Institute, St. George's
University of London, London, UK
- Sean Pokorney, MD, MBA, Director
of the Arrhythmia Core Laboratory, Duke Clinical Research
Institute, Assistant Professor of Medicine, Duke University School of Medicine, Durham, NC
To access the live call by phone, dial (877) 870-4263 (domestic)
or (412) 317-0790 (international) and ask to be connected to the
Milestone Pharmaceuticals call. To access a live or recorded
webcast of the event and accompanying slides, please visit the News
& Events section of Milestone's investor relations website
at investors.milestonepharma.com.
About Atrial Fibrillation with Rapid Ventricular
Rate
An estimated five million Americans suffer from atrial
fibrillation (AFib), a common arrhythmia marked by an irregular,
disruptive and often rapid heartbeat. Incidence of atrial
fibrillation (AFib) in the United
States is expected to grow to approximately 10 million
by 2025 and up to about 12 million by 2030. A subset of AFib
patients experience episodes of abnormally high heart rate most
often accompanied by palpitations, shortness of breath, dizziness,
and weakness. While these episodes, known as AFib-RVR, may be
treated by oral calcium channel blockers and/or beta blockers,
patients frequently seek acute care in the emergency department to
address symptoms. In 2016, nearly 800,000 patients were admitted to
the emergency department due to AFib symptoms where treatment
includes medically supervised intravenous administration of calcium
channel blockers or beta blockers, or electrical cardioversion.
With little available data for AFib-RVR, Milestone's initial market
research indicates that 30-40% of patients with AFib experience one
or more symptomatic episodes of RVR per year that require
treatment, suggesting a target addressable market of approximately
three to four million patients in 2030 for etripamil in patients
with AFib.
About Etripamil
Etripamil is Milestone's lead investigational product. It is a
novel calcium channel blocker nasal spray under clinical
development for elevated and often highly symptomatic heart-rate
attacks associated with paroxysmal supraventricular tachycardia
(PSVT) and atrial fibrillation with a rapid ventricular rate
(AFib-RVR). It is designed to be a rapid-response therapy that is
self-administered by the patient, without the need for direct
medical oversight. If approved, etripamil is intended to provide
health care providers with a new treatment option to enable on
demand care and patient self-management. If approved, the portable
treatment, studied as self-administered, may provide patients with
active management and a greater sense of control over their
condition. Etripamil, proposed brand name CARDAMYST™, is well
studied with a robust clinical trial program that includes a
completed Phase 3 clinical-stage program for the treatment of PSVT
and Phase 2 proof-of-concept trial for the treatment of patients
with AFib-RVR.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a
biopharmaceutical company developing and commercializing innovative
cardiovascular medicines to benefit people living with certain
heart conditions. Milestone recently submitted a New Drug
Application (NDA) to the U.S. Food and Drug Administration (FDA)
for etripamil for treatment of an abnormal heart rhythm, paroxysmal
supraventricular tachycardia or PSVT. Find out more
at www.milestonepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "believe," "continue," "could," "demonstrate,"
"designed," "develop," "estimate," "expect," "may," "pending,"
"plan," "potential," "progress," "will" and similar expressions (as
well as other words or expressions referencing future events,
conditions, or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Milestone's expectations and assumptions as of the date of
this press release. Each of these forward-looking statements
involves risks and uncertainties. Actual results may differ
materially from these forward-looking statements. Forward-looking
statements contained in this press release include statements
regarding the anticipated growth of incidence of AFib and AFib-RVR
by 2030; and the ability of etripamil to act as a rapid-response
therapy that is self-administered by the patient, without the need
for direct medical oversight and to provide health care providers
with a new treatment option to enable on demand care and patient
self-management. Important factors that could cause actual results
to differ materially from those in the forward-looking statements
include, but are not limited to, the risks inherent in
biopharmaceutical product development and clinical trials,
including the lengthy and uncertain regulatory approval process;
uncertainties related to the timing of initiation, enrollment,
completion, evaluation and results of our clinical trials; risks
and uncertainty related to the complexity inherent in cleaning,
verifying and analyzing trial data; and whether the clinical trials
will validate the safety and efficacy of etripamil for PSVT or
other indications, among others, general economic, political, and
market conditions, including deteriorating market conditions due to
investor concerns regarding inflation and Russian hostilities in
Ukraine and overall fluctuations
in the financial markets in the United
States and abroad, risks related to pandemics and public
health emergencies, and risks related the sufficiency of
Milestone's capital resources and its ability to raise additional
capital in the current economic climate. These and other risks are
set forth in Milestone's filings with the U.S. Securities and
Exchange Commission, including in its annual report on Form 10-K
for the year ended December 31, 2022,
under the caption "Risk Factors," as such discussion may be updated
from time to time by subsequent filings, we may make with the U.S.
Securities and Exchange Commission. Except as required by law,
Milestone assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Contact
Kim Fox, Vice
President, Communications
kfox@milestonepharma.com
704-803-9295
View original content to download
multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-host-investor-and-analyst-webcast-to-review-data-from-revera-phase-2-study-of-etripamil-in-afib-rvr-301979965.html
SOURCE Milestone Pharmaceuticals, Inc.